Home Reimbursed medicines Denosumab
Denosumab — maximum prices and reimbursement
The CANAMED catalogue contains 24 medicines with the active substance Denosumab, from 9 manufacturers. Below you can see each entry with the brand name, the manufacturer, the maximum retail price, the reimbursement percentage and the prescription status — plus live pharmacy prices, where we track them.
In short: for the active substance Denosumab there are 24 authorised medicines in the CANAMED catalogue, with maximum retail prices between 507.13 and 1202.90 RON, from 9 manufacturers. For 17 of them the catalogue also records the reimbursement percentage. The maximum price is the legal cap — pharmacies may sell below it, so it is worth comparing the real price before you go. Latest import: 2026-11-03.
Data verified on from public sources (OpenStreetMap, chain websites, ANM/MS) — updated daily.
CANAMED catalogue
All medicines with Denosumab
Maximum retail price = the legal selling cap. Sorted by price, lowest first.
| Brand name | Manufacturer | Maximum price | Reimbursement | Prescription |
|---|---|---|---|---|
| STOBOCLO 60 mg | NUVISAN FRANCE S.A.R.L - FRANTA | 507.13 RON | 100% · C1 (certain chronic diseases) CNAS pays ~507.13 RON; you ~0.00 RON* |
PRF |
| JUNOD 60 mg | GEDEON RICHTER PLC. - UNGARIA | 571.65 RON | 100% · C1 (certain chronic diseases) CNAS pays ~571.65 RON; you ~0.00 RON* |
PRF |
| JUBBONTI 60 mg | NOVARTIS PHARMACEUTICAL MANUFACTURIN - AUSTRIA | 581.03 RON | 100% · C1 (certain chronic diseases) CNAS pays ~581.03 RON; you ~0.00 RON* |
PRF |
| KEFDENSIS 60 mg | ALVOTECH HF - ISLANDA | 607.81 RON | 100% · C1 (certain chronic diseases) CNAS pays ~607.81 RON; you ~0.00 RON* |
PRF |
| OSVYRTI 60 mg | ACCORD HEALTHCARE POLSKA SP. Z O.O. - POLONIA | 607.81 RON | 100% · C1 (certain chronic diseases) CNAS pays ~607.81 RON; you ~0.00 RON* |
PRF |
| ZADENVI 60 mg | GH GENHELIX S.A. - SPANIA | 607.81 RON | 100% · C1 (certain chronic diseases) CNAS pays ~607.81 RON; you ~0.00 RON* |
PRF |
| PROLIA | AMGEN EUROPE B.V. - OLANDA | 741.74 RON | 100% · C1 (certain chronic diseases) CNAS pays ~608.56 RON; you ~133.18 RON* |
PRF |
| OSENVELT 120 mg | NUVISAN FRANCE S.A.R.L - FRANTA | 789.64 RON | 100% · C2 (national programmes) CNAS pays ~789.64 RON; you ~0.00 RON* |
PR |
| XBRYK 120 mg | SAMSUNG BIOEPIS NL B.V. - OLANDA | 828.66 RON | 100% · C2 (national programmes) CNAS pays ~828.66 RON; you ~0.00 RON* |
PR |
| YAXWER 120 mg | GEDEON RICHTER PLC. - UNGARIA | 868.26 RON | 100% · C2 (national programmes) CNAS pays ~868.26 RON; you ~0.00 RON* |
PR |
| ENWYLMA 120 mg | GH GENHELIX S.A. - SPANIA | 869.13 RON | 100% · C2 (national programmes) CNAS pays ~869.13 RON; you ~0.00 RON* |
PR |
| DENBRAYCE 120 mg | GH GENHELIX S.A. - SPANIA | 869.37 RON | 100% · C2 (national programmes) CNAS pays ~869.37 RON; you ~0.00 RON* |
PR |
| JUBEREQ 120 mg | ACCORD HEALTHCARE POLSKA SP. Z O.O. - POLONIA | 869.37 RON | 100% · C2 (national programmes) CNAS pays ~869.37 RON; you ~0.00 RON* |
PR |
| WYOST 120 mg | LEK PHARMACEUTICALS D.D. - SLOVENIA | 869.37 RON | 100% · C2 (national programmes) CNAS pays ~869.37 RON; you ~0.00 RON* |
PR |
| ZVOGRA 120 mg | ALVOTECH HF - ISLANDA | 869.37 RON | 100% · C2 (national programmes) CNAS pays ~869.37 RON; you ~0.00 RON* |
PR |
| XGEVA 120 mg | AMGEN EUROPE B.V. - OLANDA | 1202.90 RON | 100% · C2 (national programmes) CNAS pays ~947.57 RON; you ~255.33 RON* |
PR |
| XGEVA 120mg | AMGEN EUROPE B.V. - OLANDA | 1202.90 RON | 100% · C2 (national programmes) CNAS pays ~947.57 RON; you ~255.33 RON* |
PR |
| OBODENCE 60 mg | SAMSUNG BIOEPIS NL B.V. - OLANDA | — | not reimbursed | PRF |
| PROLIA | AMGEN EUROPE B.V. - OLANDA | — | not reimbursed | PRF |
| PROLIA | AMGEN EUROPE B.V. - OLANDA | — | not reimbursed | PRF |
| XBRYK 120 mg | SAMSUNG BIOEPIS NL B.V. - OLANDA | — | not reimbursed | PR |
| YAXWER 120 mg | GEDEON RICHTER PLC. - UNGARIA | — | not reimbursed | PR |
| YAXWER 120 mg | GEDEON RICHTER PLC. - UNGARIA | — | not reimbursed | PR |
| ZVOGRA 120 mg | ALVOTECH HF - ISLANDA | — | not reimbursed | PR |
Reimbursement and amounts come from the CNAS nomenclature (SIUI) valid in the current month, for each pack. *What you pay is indicative: the maximum price minus what CNAS pays on the main sublist, for an insured adult. The pharmacy may sell below the maximum price; low-income pensioners, children, pupils and pregnant women may pay less. C1 applies only to the diseases on the list, and C2 within the national programmes.
Prescription status key:
- PRF — With a medical prescription kept by the pharmacy (P-RF)
- PR — With a medical prescription (PR)
Live pharmacy prices
Products with Denosumab in our comparator
Shelf prices collected from the large chains — see on each product page where it is cheapest.
Good to know
How to read the maximum price
The CANAMED maximum retail price is the legal cap approved by the Ministry of Health — the pharmacy may sell for less, never for more. If the medicine is reimbursed, the sublist percentage (A 90%, B 50%, C1/C2 100%, D 20%) applies to the reference price of the therapeutic group, usually calculated from the cheapest product with the same INN — which is why your contribution can differ from one brand to another, even for the same active substance. The electronic prescription automatically shows the exact amount to pay; for non-prescription shelf prices, use the HartaFarmacii comparator.
CANAMED catalogue
Other active substances in the catalogue
- Dabigatran etexilat
- Dapagliflozin
- Diclofenac
- Duloxetin
- Desloratadin
- Donepezil
- Dexamethason
- Dimethyl fumarate
- Dasatinib
- Diverse
See also the full list of reimbursed medicines, with an alphabetical index of all active substances.
Frequently asked questions
FAQ · Denosumab
-
Is Denosumab reimbursed?
Yes. For 17 of the catalogue entries with Denosumab we have the reimbursement percentage on record. The percentage depends on the CNAS sublist each product is placed on (A 90%, B 50%, C1/C2 100%, D 20%) and applies to the reference price of the therapeutic group, not to the shelf price. Ask the doctor or pharmacist for the exact placement. -
What is the CANAMED maximum price for Denosumab?
The maximum retail prices (the CANAMED legal cap) for medicines with Denosumab are between 507.13 and 1202.90 RON. No pharmacy may sell above the maximum price, but it may sell below it — compare real prices with the HartaFarmacii comparator. -
What percentage of Denosumab is reimbursed?
The percentage depends on the CNAS sublist: A 90% (common chronic diseases), B 50% (partial reimbursement), C1 and C2 100% (serious chronic diseases and national programmes), D 20%. The percentage applies to the reference price set by CNAS, not to the shelf price, so you may pay a difference even for a “100% reimbursed” medicine. You can see the exact placement on the electronic prescription. -
How many medicines with Denosumab are in the CANAMED catalogue?
The CANAMED catalogue holds 24 authorised medicines with the active substance Denosumab — different brand names, strengths and pharmaceutical forms. You will find them all, with maximum price and prescription status, in the table on this page. Latest CANAMED import into the HartaFarmacii database: 2026-11-03.
Before you go